Business
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelar...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n\n\n\n\n\n\n\n- AWARE-1 trial demonstrates pelareorep primes an adaptive immune response\n- Systemic delivery yields robust pelareorep replication selectively in tumor cells\n- Pelareorep administration increases CelTIL - known to be associated with positive clinical outcomes\n- Peripheral T cell clonality emerges as potential predictive and prognostic biomarker\nCanada NewsWire\nSAN DIEGO and CALGARY, Alberta, May 26, 2020\n\n\n\nSAN DIEGO and CALGARY, Alberta, May 26, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study. The data demonstrates a pelareorep-induced adaptive immune response in the tumor microenvironment (TME) and the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep. The ePoster was published on May 23, 2020, and presented over the weekend, as part of the European Society for Medical Oncology Breast Cancer Virtual Meeting.\n\"The preliminary AWARE-1 data showing a pelareorep-induced adaptive immune response in the tumor microenvironment are highly encouraging and strongly support the trial design and rationale,\" said Dr. Aleix Prat, co-author and lead translational investigator for the AWARE-1 study. \"Observed increases in CelTIL, which are associated with a favorable response to treatm...